Product Information
TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE) is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $0.1256 per EA under NDC 68462068501. Its NADAC has been published 293 times since Jan 13, 2021.
FDA first approved this application on Nov 10, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.5 mg/1
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462068501
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
TACROLIMUSApproval Type
Generic (ANDA)
FDA Application
ANDA206662FDA Approved
11/10/2020
TE Code
AB
On Market Since
11/10/2020
Pharmacological Classes
Price Statistics
The NADAC for TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE) has been published 293 times since Jan 13, 2021, and over the history we have for it it has declined 79.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1256 per EA |
|---|---|
| All-time high | $0.6185 (Jan 13, 2021) |
| All-time low | $0.1091 (Nov 20, 2024) |
| 52-week high | $0.1744 |
| 52-week low | $0.1256 |
| Median price | $0.1823 |
| Average price | $0.2114 |
| Largest weekly change | +49.0% (Jun 19, 2024) |
| Weeks tracked | 293 |
| Tracking since | Jan 13, 2021 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE)?
The current National Average Drug Acquisition Cost (NADAC) for TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE), manufactured by Glenmark Pharmaceuticals Inc., USA, is $0.1256 per EA (NDC 68462068501), effective Aug 19, 2026.
How has the price of TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE) changed over time?
Over the history we have for it, the NADAC for TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE) has declined 79.7%. It has been tracked across 293 weekly CMS publications since Jan 13, 2021.
What are the highest and lowest recorded NADAC prices for TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE)?
Since Jan 13, 2021, the NADAC for TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE) has ranged from a low of $0.1091 (Nov 20, 2024) to a high of $0.6185 (Jan 13, 2021), with a median of $0.1823 per EA.
Are there cheaper alternatives to TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE)?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE) in a comparable dosage form, but none are currently priced below it.
Who manufactures TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE)?
TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE) (NDC 68462068501) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.